Rs 66 lakh acquisition will support DNA engineering and novel cell-gene therapy alternatives to conventional chemotherapy
The company has highlighted setbacks in Phase II studies while outlining fresh regulatory and late-stage development plans for Fibromun and Nidlegy
Parliament clears reform bill replacing jail terms for procedural lapses with graded monetary penalties across key health laws
ANDA approval for 100 mg and 150 mg capsules targeting idiopathic pulmonary fibrosis opens access to a $3.76 billion market in USA
Industry, policymakers focus on AI-led regulatory harmonisation, FTAs, MSME support and market expansion as exports touch $28.29 billion till February FY26
Developed for today’s fast-paced, visually demanding lifestyles, the lenses are built on ZEISS NeurOptix technology
The SirPAD trial marks a significant milestone in vascular intervention, positioning MagicTouch PTA as a promising future alternative for PAD treatment
DBT-BIRAC, BioE3 and the Rs 10,000-crore Biopharma SHAKTI scheme aim to accelerate innovation, biomanufacturing and exports
Empowering 15 Women in STEM (Life Sciences) with scholarship, internship and mentorship
As of December 31, 2025, the company reported total cash, cash equivalents and short-term investments of approximately $4.94 million
Subscribe To Our Newsletter & Stay Updated
